Celltrion's autoimmune disease treatment, Stekima, has surpassed a 16% prescription share in the U.S. market just over a year after its launch. The company is experiencing rapid growth in the U.S. as it expands prescriptions for its existing flagship products, Truxima and Inflectra, as well as new offerings like Uplima.
According to IQVIA, a pharmaceutical market research firm, Stekima (active ingredient: ustekinumab) recorded a 16.2% prescription share in the U.S. ustekinumab biosimilar market as of July. This marks a 6 percentage point increase from 10.2% in February, just five months prior. The U.S. ustekinumab market is estimated to be worth around 20 trillion won.
From its initial launch, Stekima has been listed as a preferred medication by major pharmacy benefit managers (PBMs) and public and private insurance formularies, quickly establishing a foundation for insurance reimbursement. Celltrion's U.S. subsidiary has been strengthening its localized sales efforts targeting autoimmune disease specialists and insurance companies.
Uplima (active ingredient: adalimumab) also achieved a 9.4% prescription share during the same period. Analysts suggest that its inclusion in the formularies of two of the top three U.S. PBMs at the end of last year has significantly contributed to its prescription growth.
Celltrion's existing products continue to maintain a strong position in the U.S. market. The blood cancer treatment Truxima (active ingredient: rituximab) has held the top prescription spot for six consecutive months with a 38.6% share. Last month, Truxima became the first rituximab biosimilar to receive 'interchangeability' status from the U.S. Food and Drug Administration (FDA), allowing it to be substituted for the original product.
Inflectra (active ingredient: infliximab, marketed as Remsima in the U.S.) also retained its lead in the infliximab biosimilar market with a 30.7% prescription share.
Celltrion plans to enhance sales synergies across its product lines based on its direct sales network in the U.S. The company aims to increase prescriptions for Stekima and Uplima by leveraging its existing sales network focused on autoimmune disease treatments and strengthen its portfolio competitiveness through the launch of subsequent products.
Notably, the company is set to launch high-margin follow-up products, such as the chronic spontaneous urticaria treatment Omniclo (active ingredient: omalizumab), in the U.S. Celltrion expects that adding new products to its existing sales network will bolster revenue growth and improve profitability in the U.S. market.
A Celltrion representative stated, "Both new and existing product lines, including Stekima, are achieving significant results in the U.S. and expanding their influence. We will maximize the sales effects of our direct sales network to accelerate prescription growth and successfully launch high-margin follow-up products like Omniclo to achieve revenue growth."
Meanwhile, after achieving record results in the first half of the year, Celltrion is expected to continue its growth in the second half, driven by the expansion of new product sales and European bidding volumes. The company's annual revenue target is set at 5.3 trillion won, with an operating profit goal of 1.8 trillion won.
According to IQVIA, a pharmaceutical market research firm, Stekima (active ingredient: ustekinumab) recorded a 16.2% prescription share in the U.S. ustekinumab biosimilar market as of July. This marks a 6 percentage point increase from 10.2% in February, just five months prior. The U.S. ustekinumab market is estimated to be worth around 20 trillion won.
From its initial launch, Stekima has been listed as a preferred medication by major pharmacy benefit managers (PBMs) and public and private insurance formularies, quickly establishing a foundation for insurance reimbursement. Celltrion's U.S. subsidiary has been strengthening its localized sales efforts targeting autoimmune disease specialists and insurance companies.
Uplima (active ingredient: adalimumab) also achieved a 9.4% prescription share during the same period. Analysts suggest that its inclusion in the formularies of two of the top three U.S. PBMs at the end of last year has significantly contributed to its prescription growth.
Celltrion's existing products continue to maintain a strong position in the U.S. market. The blood cancer treatment Truxima (active ingredient: rituximab) has held the top prescription spot for six consecutive months with a 38.6% share. Last month, Truxima became the first rituximab biosimilar to receive 'interchangeability' status from the U.S. Food and Drug Administration (FDA), allowing it to be substituted for the original product.
Inflectra (active ingredient: infliximab, marketed as Remsima in the U.S.) also retained its lead in the infliximab biosimilar market with a 30.7% prescription share.
Celltrion plans to enhance sales synergies across its product lines based on its direct sales network in the U.S. The company aims to increase prescriptions for Stekima and Uplima by leveraging its existing sales network focused on autoimmune disease treatments and strengthen its portfolio competitiveness through the launch of subsequent products.
Notably, the company is set to launch high-margin follow-up products, such as the chronic spontaneous urticaria treatment Omniclo (active ingredient: omalizumab), in the U.S. Celltrion expects that adding new products to its existing sales network will bolster revenue growth and improve profitability in the U.S. market.
A Celltrion representative stated, "Both new and existing product lines, including Stekima, are achieving significant results in the U.S. and expanding their influence. We will maximize the sales effects of our direct sales network to accelerate prescription growth and successfully launch high-margin follow-up products like Omniclo to achieve revenue growth."
Meanwhile, after achieving record results in the first half of the year, Celltrion is expected to continue its growth in the second half, driven by the expansion of new product sales and European bidding volumes. The company's annual revenue target is set at 5.3 trillion won, with an operating profit goal of 1.8 trillion won.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.